Author

Noemi Arrighetti

Fondazione IRCCS Istituto Nazionale dei TumoriORCID 0000-0001-9848-3239Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Alex KentsisiD· 2 shared Nadia ZaffaroniiD· 2 shared Valentina ZucoiD· 2 shared Alessandro GronchiiD· 1 shared Andrea CalifanoiD· 1 shared Andrew L. KungiD· 1 shared Anna Maria FrezzaiD· 1 shared Cesare SoffientiniiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Alex KentsisORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combination

Noemi Arrighetti, Cesare Soffientini, Valentina Zuco, Stefano Percio, Loredana Cleris, Suzan Abdulrazak Ahmed, Elisa Savio, Luca Sigalotti, Roberta Maestro, Silvia Brich, Gian Paolo Dagrada, Marta Barisella, Paola Collini, Alex Kentsis, Paul H. Huang, , Sandro Pasquali

This paper identifies HDAC inhibition as a strategy to overcome resistance to EZH2 inhibitors in INI1-deficient epithelioid sarcoma by restoring H3K27 acetylation and enhancing therapeutic response.

bioRxiv · Aug 4, 2026 · PreprintCancer Biology

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas

Yaniv Kazansky, Helen S. Mueller, Daniel Cameron, Phillip Demarest, Nadia Zaffaroni, Noemi Arrighetti, Valentina Zuco, Prabhjot Singh Mundi, Yasumichi Kuwahara, Romel Somwar, Rui Qu, Andrea Califano, Elisa de Stanchina, Filemon S. Dela Cruz, Andrew L. Kung, , Alex Kentsis

The paper identifies ATR as a target for combination EZH2 epigenetic therapy in SMARCB1-deficient sarcomas, showing that EZH2 inhibition promotes DNA damage via PGBD5, and that ATR inhibition enhances therapeutic responses.

Journal of Clinical Investigation · Aug 12, 2025Peer-reviewedCancer Biology